Cell-Free Methylated PTGER4 and SHOX2 Plasma DNA as a Biomarker for Therapy Monitoring and Prognosis in Advanced Stage NSCLC Patients.

Fleischhacker M, Arslan E, Reinicke D, Eisenmann S, Theil G, Kollmeier J, Schäper C, Grah C, Klawonn F, Holdenrieder S, Schmidt B

Open source

DOI
10.3390/diagnostics13132131
Published
2023 Jun 21
Container
Diagnostics (Basel, Switzerland)
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/diagnostics13132131,
  title = {Cell-Free Methylated PTGER4 and SHOX2 Plasma DNA as a Biomarker for Therapy Monitoring and Prognosis in Advanced Stage NSCLC Patients.},
  author = {Fleischhacker M and Arslan E and Reinicke D and Eisenmann S and Theil G and Kollmeier J and Schäper C and Grah C and Klawonn F and Holdenrieder S and Schmidt B},
  year = {2023},
  journal = {Diagnostics (Basel, Switzerland)},
  doi = {10.3390/diagnostics13132131},
  url = {https://doi.org/10.3390/diagnostics13132131}
}

RIS

TY  - JOUR
TI  - Cell-Free Methylated PTGER4 and SHOX2 Plasma DNA as a Biomarker for Therapy Monitoring and Prognosis in Advanced Stage NSCLC Patients.
AU  - Fleischhacker M
AU  - Arslan E
AU  - Reinicke D
AU  - Eisenmann S
AU  - Theil G
AU  - Kollmeier J
AU  - Schäper C
AU  - Grah C
AU  - Klawonn F
AU  - Holdenrieder S
AU  - Schmidt B
PY  - 2023
JO  - Diagnostics (Basel, Switzerland)
DO  - 10.3390/diagnostics13132131
UR  - https://doi.org/10.3390/diagnostics13132131
ER  - 

APA

M, F., E, A., D, R., S, E., G, T., J, K., C, S., C, G., F, K., S, H., & B, S. (2023). Cell-Free Methylated PTGER4 and SHOX2 Plasma DNA as a Biomarker for Therapy Monitoring and Prognosis in Advanced Stage NSCLC Patients.. Diagnostics (Basel, Switzerland). https://doi.org/10.3390/diagnostics13132131

Source records